Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other Working Capital Changes (2016 - 2026)

Heron Therapeutics filings provide 16 years of Other Working Capital Changes readings, the most recent being -$1.1 million for Q1 2026.

  • On a quarterly basis, Other Working Capital Changes fell 113.04% to -$1.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$10.6 million, a 157.92% decrease, with the full-year FY2025 number at -$878000.0, down 108.84% from a year prior.
  • Other Working Capital Changes hit -$1.1 million in Q1 2026 for Heron Therapeutics, up from -$5.4 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $8.6 million in Q1 2025 to a low of -$9.5 million in Q2 2023.
  • Median Other Working Capital Changes over the past 5 years was -$289000.0 (2024), compared with a mean of -$500529.4.
  • The widest YoY moves for Other Working Capital Changes: up 3775.68% in 2025, down 3118.69% in 2025.
  • Heron Therapeutics' Other Working Capital Changes stood at $4.7 million in 2022, then plummeted by 203.58% to -$4.9 million in 2023, then soared by 226.06% to $6.2 million in 2024, then crashed by 188.15% to -$5.4 million in 2025, then skyrocketed by 79.33% to -$1.1 million in 2026.
  • The last three reported values for Other Working Capital Changes were -$1.1 million (Q1 2026), -$5.4 million (Q4 2025), and $5.2 million (Q3 2025) per Business Quant data.